This excerpt taken from the NVS 6-K filed Oct 3, 2005.
24-hour efficacy in asthma and COPD
The efficacy of indacaterol in both asthma and COPD was demonstrated in a series of placebo-controlled
clinical studies using once-daily doses of indacaterol ranging from 25 to 2000 µg.(1)-(7) The duration of action of indacaterol was found to be largely independent of dose, with superior bronchodilation to placebo demonstrated at 24 hours after a single dose.(1)
The efficacy of indacaterol in patients with asthma was further investigated in three multiple-dose studies of 7, 14 and 28 days duration.(3)-(5) In these studies, the 24-hour bronchodilator efficacy of indacaterol observed on the first day was maintained for the duration of the studies, suggesting that regular use of indacaterol is not associated with the development of tolerance, or tachyphylaxis. Indacaterol also demonstrated 24-hour bronchodilator efficacy with no evidence of tachyphylaxis in patients with COPD.(6),(7)